Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on DBV Technologies SA – American and keeping the price target at $46.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sam Slutsky has given his Buy rating due to a combination of factors, including the competitive positioning of Viaskin Peanut against emerging peanut allergy therapies such as ALK-Abelló’s sublingual tablet. He appears to view DBV’s epicutaneous approach and its ED-based responder endpoint as clinically meaningful and well aligned with how regulators and clinicians assess desensitization in peanut-allergic patients.
Sam Slutsky also likely factors DBV’s manageable cash runway, reasonable burn, and modest short interest into his positive view, supporting the company’s ability to reach key value-inflection milestones. In addition, he seems to believe that, despite new SLIT data, Viaskin Peanut can retain a differentiated profile in safety, caregiver acceptability, and use in younger children, providing room for attractive upside in DBVT shares.